NIKKEI 225
32,307.86 -550.44 (-1.68%) HANG SENG
16,334.37 -11.53 (-0.07%) CRUDE OIL
71.19 -0.04 (-0.06%) GOLD FUTURES
2,021.40 +6.90 (+0.34%) DOW
36,247.87 +130.47 (+0.36%) BTC-GBP
34,849.04 +4.28 (+0.01%)
NVO Jan 2024 175.000 call
- Zacks
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.
- Motley Fool
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not be advancing into late-stage clinical trials. Now, the company's bid to capture portions of the extremely lucrative type 2 diabetes and obesity drug markets looks like it's in trouble.
- Motley Fool
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
Novo Nordisk (NYSE: NVO) is a leader in the billion-dollar weight loss market, with two drugs that have helped its earnings soar. The company sells semaglutide under the name Wegovy for weight loss and as Ozempic for type 2 diabetes. Doctors also have prescribed rival Eli Lilly's (NYSE: LLY) diabetes drug, Mounjaro, for weight management, causing sales at this big pharma to take off, too.
